Overview

Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load

Status:
Withdrawn
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This is a study of the effect of raltegravir on human T-cell leukemia virus type 1 (HTLV-1) viral load in asymptomatic patients. The study will enroll 14 subjects for a period of 2 months of treatment and 1 month of followup. The study will assess the effect of raltegravir on virus load in peripheral blood lymphocytes, level of virus gene expression, and sites of viral integration.
Phase:
Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Raltegravir Potassium